Rao, Srinivasa http://orcid.org/0000-0003-1889-6530
Verrill, Clare
Cerundolo, Lucia
Alham, Nasullah Khalid
Kaya, Zeynep
O’Hanlon, Miriam
Hayes, Alicia
Lambert, Adam
James, Martha
Tullis, Iain D. C.
Niederer, Jane
Lovell, Shelagh
Omer, Altan
Lopez, Francisco
Leslie, Tom
Buffa, Francesca
Bryant, Richard J.
Lamb, Alastair D.
Vojnovic, Boris
Wedge, David C.
Mills, Ian G.
Woodcock, Dan J.
Tomlinson, Ian
Hamdy, Freddie C.
Funding for this research was provided by:
Cancer Research UK (C1380/A18444)
NIHR Oxford Biomedical Research Centre
Article History
Received: 19 July 2023
Accepted: 6 February 2024
First Online: 19 February 2024
Declarations
:
: Patients consented to participate in this study under Research Ethics Committee approval no. 18/SC/0103, and formalin-fixed, paraffin-embedded samples were obtained through the routine histopathological diagnostic pathway under Oxford Radcliffe Biobank ethics (Research Ethics Committee approval no. 19/SC/0173) from patients who consented as above. This research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: ADL has received educational support and funding to attend meetings from Intuitive Surgical and BXT Accelyon. While acting as Chief investigator of ProMOTE Trial (2022–2023), he benefited from payment-in-kind support from Imaginab & Catalent for IAB2M-IR800 stability testing. He was a signatuory/author of the ‘TREXIT’ paper for prostate biopsy. He is co-CI of the TRANSLATE trial funded by NIHR(HTA) and lead investigator of the QUANTUM Biobank part funded by the John Black Charitable Foundation. He is personally funded by Cancer Research UK (C57899/A25812) who also fund his SPACE Study lab. He has previously received grant funding from Prostate Cancer UK (PA14-022), The Academy of Medical Sciences (SGCL11), Medical Research Council (CiC), Cambridge BRC and GlaxoSmithKline. He has received education support from Astellas, Lilly, Astrazenaca and Ipsen. He is a stipendiary BJUI Section Editor for Prostate Cancer and has received honoraria for reviewing for European Urology and Lancet Oncology. He has received consulting fees from AlphaSights. The other authors declare that they have no competing interests.